MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

169.5B

Vuru Grade

47.84/100

Current Price

$59.44
+0.46 (+0.78%)

Growth Price

$47.51
Overvalued by 20.07%

Stability Price

$23.64
Overvalued by 60.23%

Company Metrics

  • 32.11 P/E
  • 3.9 P/S
  • 3.73 P/B
  • 1.837 EPS
  • 10.80% Cash ROIC
  • 0.98 Cash Ratio
  • 1.77 / 3% Dividend
  • 11.25M Avg. Vol.
  • 2.85B Shares
  • 169.5B Market Cap.

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

5 Things Merck & Co., Inc.'s Management Wants You to Know
Motley Fool - Dec 3, 2014
It's been about a month since pharmaceutical giant Merck (NYSE: MRK ) reported its third-quarter results, but time hasn't changed the fact that Merck's been struggling mightily with patent expirations and increased competition for its key drugs.
Stock in Focus: Merck & Co., Inc. (NYSE:MRK) Looks to Growth - Markets Wired
Merck & Co. Inc. (MRK) Closes 1.02% Up on the Day for December 19
Equities.com - 9 hours ago
Merck & Co. Inc. currently has a total float of 2.85 billion shares and moves 10.14 million a day, on average. The stock opened at $59.25 on December 19 and traded between a low of $59.01 and a high of $59.90.
Cubist soars on Merck's $8.4b purchase
Boston Globe - Dec 14, 2014
Merck & Co. Inc. said last week it will proceed with its planned $8.4 billion purchase of Lexington's Cubist Pharmaceuticals Inc. and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic ...
Merck to take on superbugs with Cubist Pharma buy
Reuters - Dec 8, 2014
(Reuters) - Merck & Co Inc (MRK.N) said it would buy Cubist Pharmaceuticals Inc (CBST.O) for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.
Merck & Co., Inc. (MRK) To Buy Cubist Pharmaceuticals Inc (CBST) - Bidness ETC
In $9.5b deal, giant Merck buying Lexington's Cubist - Boston Globe
Merck & Co. (MRK) Seeks $8 Billion Bridge Loan To Acquire Cubist ...
Bidness ETC - Dec 16, 2014
Merck, the second-largest US pharmaceutical player behind Pfizer Inc. (NYSE:PFE), has chosen to stick to its decision to acquire Cubist, possibly because Cubist could have likely slapped the company with a lawsuit if Merck had got cold feet upon the ...
Breaking News: No explosive devices found in Sydney cafe siege: Australian ... - Reuters
Merck looks for US$8bn bridge for Cubist acquisition - IFR Asia
Interesting June 2015 Stock Options for Merck & Co.
Forbes - Dec 15, 2014
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the ...
Zymeworks Inc. and Merck & Co., Inc. Extend and Expand Bi-specific Antibody ...
Business Wire (press release) - Dec 9, 2014
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. today announced the extension of a research collaboration with Merck, known as MSD outside the United States and Canada, that was originally announced in August 2011. In addition ...
Merck & Co. Inc. (MRK) Closes 1.46% Up on the Day for December 17
Equities.com - Dec 17, 2014
Merck & Co. Inc. currently has a total float of 2.85 billion shares and moves 10.06 million a day, on average. The stock opened at $57.05 on December 17 and traded between a low of $56.56 and a high of $57.80.
Nike Inc, Johnson Controls Inc, Merck & Co., Inc., PulteGroup, Inc., Stocks ...
ETF Daily News - Dec 11, 2014
The big news for Merck is that it's paying $8.4 billion to buy Cubist Pharmaceuticals (NASDAQ: CBST). The big benefit of the deal is that it gives Merck a stronger presence in hospitals and antibiotics - a couple fast-growing areas of the pharma ...
Can Newly Approved Gardasil 9 Boost Merck & Co.'s (MRK) Vaccine Business?
Bidness ETC - Dec 11, 2014
Merck & Co., Inc. (NYSE:MRK) received a dose of good news yesterday as the US Food and Drug Administration (FDA) announced approval of the company's Gardasil 9 vaccine for the prevention of certain cancers caused by nine types of Human ...
New HPV vaccine strengthens cancer protection - wwlp.com
FDA approves Gardasil 9 for prevention of certain cancers caused by five ... - FDA.gov